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Recently, we reported that two siblings presenting with the clinical syndrome congenital disorders of glycosylation
(CDG) have mutations in the gene encoding Cog7p, a member of the conserved oligomeric Golgi (COG) complex. In this
study, we analyzed the localization and trafficking of multiple Golgi proteins in patient fibroblasts under a variety of
conditions. Although the immunofluorescent staining pattern of several Golgi proteins was indistinguishable from
normal, the staining of endoplasmic reticulum (ER)-Golgi intermediate compartment (ERGIC)-53 and the vesicular-
soluble N-ethylmaleimide-sensitive factor attachment protein receptors GS15 and GS28 was abnormal, and the steady-
state level of GS15 was greatly decreased. Retrograde transport of multiple Golgi proteins to the ER in patient fibroblasts
via brefeldin A-induced tubules was significantly slower than occurs in normal fibroblasts, whereas anterograde protein
trafficking was much less affected. After prolonged treatment with brefeldin A, several Golgi proteins were detected in
clusters that colocalize with the microtubule-organizing center in patient cells. All of these abnormalities were normalized
in COG7-corrected patient fibroblasts. These results serve to better define the role of the COG complex in facilitating
protein trafficking between the Golgi and ER and provide a diagnostic framework for the identification of CDG defects
involving trafficking proteins.
INTRODUCTION
The congenital disorders of glycosylation (CDG) are a group
of autosomal recessive multisystem disorders typically de-
fined by defects in proteins directly involved in the N-linked
glycosylation pathway (Freeze, 2001; Marquardt and
Denecke, 2003). The molecular defects resulting in CDG
were recently expanded to include proteins involved in
overall Golgi function. Specifically, two siblings were de-
scribed with a fatal form of CDG (classified as CDG-IIe)
caused by mutation in the gene encoding Cog7p, a member
of the conserved oligomeric Golgi (COG) complex (Wu et al.,
2004). Fibroblasts from these patients are deficient in COG
subunits 5–8 that compromise lobe B of the complex and
exhibit subtle decreases in the sialylation of both N- and
O-linked oligosaccharides (Wu et al., 2004; Oka et al., 2005).
The glycosylation defects were COG dependent because
they were effectively rescued by transduction of CDG-IIe
fibroblasts with wild-type COG7 cDNA.
The vesicle tethering COG complex is thought to mediate
numerous steps in anterograde and retrograde transport
within the secretory apparatus (reviewed in Oka and
Krieger, 2005). A role for the COG complex in maintaining
the fidelity of retrograde transport within the Golgi has been
supported by recent evidence indicating that acute depletion
of COG3 prevents tethering of retrograde vesicles within the
Golgi resulting in the accumulation of Golgi proteins, in-
cluding the soluble N-ethylmaleimide-sensitive factor at-
tachment protein receptors (SNAREs) GS15 and GS28 in COG
complex-dependent (CCD) vesicles (Zolov and Lupashin,
2005). Because resident Golgi proteins such as glycosylation
enzymes are known to recycle within the Golgi stack and
between the Golgi and ER, these findings support the gen-
eral hypothesis that altered trafficking of these proteins re-
sults in their mislocalization, altered activity, possible deg-
radation, or a combination. Indeed, a role for the COG
complex in controlling the abundance of a subset of Golgi
proteins (including glycosylation enzymes) in Chinese ham-
ster ovary (CHO) cells has been recently demonstrated by
Krieger and colleagues (Oka et al., 2004).
In contrast, a role for the COG complex in trafficking
events between the endoplasmic reticulum (ER) and Golgi is
less established (Sztul and Lupashin, 2006). Studies in COG-
deficient yeast mutants suggest that COG may play a role in
ER export and ER-to-Golgi transport (VanRheenen et al.,
1998, 1999; Morsomme et al., 2003). In support of a functional
role for the COG complex in trafficking between the ER and
Golgi, we observed slower recovery of Golgi localization of
a green fluorescent protein (GFP)-sialyltransferase chimera
after photobleaching in patient fibroblasts (Wu et al., 2004).
Despite the fact that slower recovery of Golgi localization
can most directly be interpreted by a block in anterograde
transport, the directionality of transport affected was not
conclusive from these experiments because preexisting pro-
tein in intermediate compartments (i.e., ER-Golgi interme-
diate compartment [ERGIC]) may move slowly back to the
ER before entering the Golgi.
In the present study, we have analyzed the localization
and trafficking of multiple Golgi- and ERGIC-localized pro-
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teins in control and COG7-deficient patient fibroblasts under
several different conditions with the goal of better defining
the intracellular membrane trafficking pathways perturbed
by the Cog7p defect. Our findings reveal a number of alter-
ations in protein trafficking and stability in the COG7-defi-
cient cells under steady-state conditions. Furthermore,
brefeldin A (BFA) treatment of COG7-deficient fibroblasts
unveils several additional defects in the localization and
trafficking of Golgi proteins. The implications of these find-
ings on the function of the COG complex, the clinical fea-
tures in CDG-IIe patients, and the diagnosis of other COG-
deficient patients are discussed.
MATERIALS AND METHODS
Reagents and Antibodies
Reagents and sources were as follows: ECL Plus detection kit (Amersham
Biosciences, Piscataway, NJ), methionine- and cysteine-free Ham’s F-12 me-
dium (Invitrogen, Carlsbad, CA), Trans 35S protein labeling mix (MP Bio-
medicals, Irvine, CA), MG132 (Calbiochem, San Diego, CA), protease inhib-
itor cocktail (Roche Diagnostics, Indianapolis, IN), and BFA (Calbiochem)
prepared in stock solutions (5 mg/ml) with dimethyl sulfoxide. All other
reagents including leupeptin and pepstatin A were obtained from Sigma-
Aldrich (St. Louis, MO).
Antibodies used for immunoblot (IB) and immunofluorescence (IF) studies
were obtained from standard commercial sources and as gifts from generous
individual investigators (see below). Antibodies (and their appropriate dilu-
tions) were as follows: rabbit polyclonal antibodies: anti-GPP130 antibody (IB,
1:500; IF, 1:250; Covance, Berkeley, CA), anti-giantin antibody (IB, 1:2000; IF,
1:1000; Covance), and anti- COP antibody (IF, 1:2000; Abcam, Cambridge,
MA); and murine monoclonal antibodies: anti-ERGIC-53 antibody (IF, 1:500;
a generous gift from Dr. Hans-Peter Hauri, University of Basel, Basel, Swit-
zerland), anti-1,4-galactosyltransferase (GalT) antibody (clone 36/118; IB,
1:20; IF, 1:50; a generous gift from Dr. Eric Berger, University of Zurich,
Zurich, Switzerland), anti-GM130 antibody (IF, 1:100; IB, 1:250; BD Bio-
sciences, San Jose, CA), anti-GS28 antibody (IB, 1:3000; IF, 1:1000; BD Bio-
sciences), anti-GS15 antibody (IB, 1:250, IF, 1:100; BD Biosciences), anti-GS27
antibody (IB, 1:1000; IF, 1:250; BD Biosciences), anti--adaptin antibody (IF,
1:500; BD Biosciences), anti--tubulin (IF, 1:1000; Sigma-Aldrich), and anti--
tubulin (IB, 1:5000; Sigma-Aldrich). Alexa Fluor-conjugated secondary anti-
bodies for immunofluorescence were obtained from Invitrogen, and species-
specific horseradish peroxidase-conjugated secondary antibodies used for
Western blotting were purchased from Amersham Biosciences.
Cell Lines
Fibroblasts were maintained in DMEM supplemented with 10% fetal bovine
serum and 100 U/ml penicillin and 100 U/ml streptomycin. COG7-corrected
cells were prepared by retroviral transduction of patient fibroblasts as de-
scribed previously (Wu et al., 2004). In experiments where cells were grown at
15°C, plates were sealed with parafilm and incubated in a temperature-
controlled environment inside a cold room. The proteasome inhibitor MG132
was added to cultures to a final concentration of 25 M for 10 h before
Western blot analysis. Inhibition of lysosomal proteases was achieved by
addition of 150 M leupeptin and 100 M pepstatin A to the culture medium
for 16 h before analysis.
BFA-induced Retrograde and Anterograde Transport
Experiments
Cells were treated with various concentrations of BFA (1 or 5 g/ml) for the
retrograde and coat release experiments. Cell populations for any given
experiment were routinely quantitated in a blinded manner. For the recovery
experiments, BFA-containing media were removed by aspiration followed by
three washes with phosphate-buffered saline (PBS) (PBS containing 1 mM
Ca2 and Mg2) to prevent cell loss. Coverslips were then removed from the
wells and washed carefully on both sides with PBS before being placed in
new wells containing fresh media warmed to 37°C. A lower concentration of
BFA (0.25 g/ml) was used for these experiments to achieve washout of the
drug in fibroblasts. Likewise, longer treatment times were necessary at this
concentration to fully redistribute Golgi proteins to the ER. Reversal of the
effects of BFA could not be accomplished in a shorter time scale in these cells
despite exhaustive measures (described above) to washout the drug and may
be attributed to differences in the sensitivity to the drug and/or cell perme-
ability.
Immunoblotting and Indirect Immunofluorescence
Microscopy
For the determination of protein levels, cells were grown at 37°C in culture
medium to near confluence, harvested, and solubilized by addition of SDS
lysis buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, and 10% glycerol) with
scraping, and heated at 95°C for 5–10 min. The lysates (60 g of protein) were
then fractionated by SDS-polyacrylamide (8 and 12%) gel electrophoresis, and
the proteins were transferred to nitrocellulose membranes (Bio-Rad, Hercules,
CA) and immunoblotted with the indicated antibodies using the ECL Plus
detection kit (Amersham Biosciences) according to the manufacturer’s in-
structions. Protein concentration in lysates was determined using the
MicroBCA protein assay reagent kit (Pierce Chemical, Rockford, IL). Cells
grown on coverslips were fixed with 3% paraformaldehyde, stained, and
analyzed by immunofluorescence microscopy as described previously (Ghosh
et al., 2003). The standard dilution buffer for primary and secondary antibod-
ies contained PBS, pH 7.4, 0.1% Triton X-100, and 1 mg/ml bovine serum
albumin. The slides were viewed with an Eclipse fluorescence microscope
(model E-800; Nikon, Tokyo, Japan), and images were acquired using a
Magnafire camera system from Optronics (Goleta, CA). Images were pre-
pared using Adobe Photoshop (Adobe Systems, Mountain View, CA), and
only linear adjustments were made.
Confocal Microscopy
Confocal images were acquired using an Olympus FV500 laser scanning
microscope equipped with a 60 oil immersion (numerical aperture 1.4)
objective. Stacks of 0.25 M (based on calculated optimums) optical sections
were collected in the z-dimension. Each stack was subsequently collapsed into
a single image (maximum intensity or z-projection), and further analyses
were performed offline using the MetaMorph software (Molecular Devices,
Sunnyvale, CA).
CD59 Immunoprecipitation Experiments
Cells grown at 37°C until 80–90% confluent were pulse labeled with [35S]cys-
teine in cysteine-free media for 20 min and chased for various times. Lysates
were prepared by scraping cells on ice in cell lysis buffer (CLB; 10 mM Tris,
pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 0.05% SDS, and protease inhibitor
cocktail). Newly synthesized CD59 was immunoprecipitated overnight using
a monoclonal antibody to human CD59 (Serotec, Oxford, United Kingdom).
After addition of protein A-agarose beads, samples were washed four times
with CLB before elution of labeled CD59 molecules and analysis by SDS-
PAGE and autoradiography.
RESULTS
Retrograde Trafficking of Golgi Proteins Is Altered in
COG7-deficient Fibroblasts
We first sought to clarify the direction of transport between
the ER and Golgi that was affected in COG7-deficient cells.
For these studies, we used the fungal metabolite BFA, a
selective inhibitor of the GTP-exchange factor for ADP-ribo-
sylation factor (ARF) that induces rapid collapse of the Golgi
apparatus into the ER via tubule-like structures (Lippincott-
Schwartz et al., 1989, 1990). In the initial experiments, control
and patient (P1) fibroblasts were treated with BFA and the
localization of the Golgi matrix protein giantin was observed
at various times in fixed cells (Figure 1). No detectable
differences were noted in the localization of giantin in un-
treated cells (Figure 1A). After 12-min treatment with BFA,
nearly all the control fibroblasts exhibited a staining pattern
consistent with ER localization. In contrast, giantin re-
mained predominantly localized to the Golgi ribbon at this
time point in P1 fibroblasts indicating a delay in the effects of
BFA. To gain a more quantitative assessment of the delayed
response to BFA observed in the mutant fibroblasts, cells
within a given population were classified into one of four
staining patterns that reflect the various stages of Golgi
collapse into the ER (Figure 1B). Whereas the majority of
control cells exhibited ER staining for giantin (pattern 4)
after 12-min treatment with BFA, only a small proportion of
P1 cells displayed complete redistribution of giantin to the
ER at this time point (70 versus 6%). The majority (79%) of
P1 cells showed incomplete Golgi collapse (patterns 2 and 3),
whereas a small fraction (15%) exhibited no observable al-
teration in Golgi ribbon structure (pattern 1; Figure 1B).
Fibroblasts from the sibling of P1 (termed P2) displayed an
identical delay in the response to BFA (our unpublished
data).
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The kinetics of the Golgi collapse is shown in Figure 1C,
where the percentage of cells with an exclusive ER staining
pattern is plotted as a function of time. Extrapolation of t1/2
values (time at which 50% of the cells exhibit an ER staining
pattern) reveals that Golgi collapse is roughly 2.5 times
slower in P1 fibroblasts (t1/2 of 24 min) relative to control
cells (t1/2 of 10 min). The delayed response to BFA was
COG7 dependent because BFA-treated COG7-corrected P1
fibroblasts are nearly indistinguishable from control cells
(Figure 1, A and B) and displayed similar kinetics of Golgi
collapse (t1/2 of 13 min). The lack of complete correction of
the delay in COG7-corrected P1 cells is likely due to not all
cells within the population being transduced with retrovirus
containing wild-type COG7 cDNA. Similar results were ob-
served with the Golgi enzyme GalT (Supplemental Figure
S1), demonstrating that the block in Golgi-to-ER retrograde
transport in COG7-deficient cells is not selective for matrix
proteins.
Release of coat proteins from Golgi membranes is one of
the earliest detectable changes in cells treated with BFA and
is necessary for tubule formation (Donaldson et al., 1990;
Lippincott-Schwartz, 1993). The delayed onset of BFA-in-
duced Golgi collapse could therefore be due to slower coat
protein release after ARF inactivation. The initial release of
two coat proteins, the Golgi COPI component COP and the
trans-Golgi network adaptor AP-1, was examined after BFA
treatment, and the results are shown in Figure 2. Whereas
COP is localized primarily to the Golgi in control and
patient cells, a shift in its distribution to the cytoplasm
occurred rapidly in both cell types and was complete after
only 3-min exposure to BFA. The release of AP-1 from the
trans-Golgi network was somewhat slower compared with
COP in control and patient fibroblasts. As seen with COP,
no difference in the initial kinetics of AP-1 release could be
detected. Therefore, the delayed Golgi collapse after BFA
treatment in patient fibroblasts occurs after ARF-guanine-
nucleotide exchange factor inhibition and coat protein re-
lease.
We next examined anterograde movement of giantin from
the ER back to the Golgi after treatment and washout of
BFA. After 60 min. treatment, 95% of both control and P1
fibroblasts exhibited a predominantly ER staining pattern
for giantin. Importantly, single giantin-positive clusters
were observed in nearly all patient cells (Table 1, see arrows
at 0 h recovery time). These clusters, detected in a small
percentage of control cells (5%) as well, became most
apparent after prolonged BFA treatment. At each time point
of recovery, qualitatively similar staining patterns were ob-
Figure 1. BFA-induced retrograde transport of the Golgi matrix
protein giantin is delayed in COG-deficient patient fibroblasts. (A)
Control, patient, and COG7-corrected patient fibroblasts were
treated with 5 g/ml BFA for 12 min, and the localization of giantin
was analyzed by immunofluorescence. Bar, 20 m. (B) Stained cells
within a population (200–300) were classified into one of four
typical staining patterns (1–4) reflecting the BFA-induced collapse
of the Golgi into the ER. Pattern 1, intact Golgi ribbon; pattern 2,
early tubule formation; pattern 3, overt tubulation and loss of ribbon
structure; and pattern 4, ER localization. The relative percentage of
cells in a representative experiment within these classifications is
shown. Highly similar percentages were observed in independent
experiments. The arrows indicate BFA-induced tubules. (C) The
percentage of cells with an exclusive ER staining pattern was plot-
ted as a function of time. The data represent the average of three
independent experiments; errors bars indicate standard deviations.
The symbols are as follows: control, closed circles; P1, closed
squares; and COG7-corrected P1, closed triangles.
Figure 2. Initial kinetics of coat protein release are not altered in
patient fibroblasts after BFA treatment. Control and patient fibro-
blasts were treated with or without 1 g/ml BFA for various times
and the localization of COP and AP-1 was followed by immuno-
fluorescence. Bar, 20 m.
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served (Figure 3A). To obtain a quantitative assessment,
cells were classified into one of four typical staining patterns
that reflect the emergence of giantin from the ER back to the
Golgi (Figure 3B). Complete recovery of the localization of
giantin into a ribbon-like Golgi structure (pattern 4r) was
slightly delayed in P1 fibroblasts (73  2 versus 55  5% at
4-h washout). This delay, however, was much less striking
compared with the differences observed for BFA-induced
retrograde transport (Figure 1). Similar results were ob-
tained with GalT (Supplemental Figure S2). GalT-positive
membrane clusters were also noted in patient fibroblasts,
although these unique structures were often less defined,
seen in fewer cells compared with giantin, and not detect-
able in control cells (Table 1).
Because a small delay in the return of resident proteins to
the Golgi after BFA washout was observed, we investigated
whether the transport of cargo proteins from the ER-to-
Golgi might be altered in COG7-deficient fibroblasts. In-
deed, experiments in COG-deficient yeast cells have sug-
gested that subunits of the COG complex play a role in
protein sorting upon ER export of glycosylphosphatidylino-
sitol (GPI)-linked proteins (Morsomme and Riezman, 2002).
Pulse-chase experiments were performed to follow the for-
ward transport of the GPI-linked protein CD59 in control
and P1 cells. The addition of N- and O-linked oligosaccha-
rides on CD59 results in changes in the size of this molecule
and indicates its transport from the ER into the Golgi (Rudd
et al., 1997). No detectable difference in the maturation of
CD59 was observed between control and P1 fibroblasts pro-
viding further support for the selective nature of protein
transport defect in COG7-deficient cells (Supplemental Fig-
ure S3). This observation is consistent with our previous
finding that the sorting of the lysosomal enzyme cathepsin D
(a measure of both ER-to-Golgi and Golgi-to-lysosome trans-
port) was not detectably altered in COG7-deficient fibro-
blasts (Wu et al., 2004).
Localization and Stability of Golgi Proteins in Control
and Patient Fibroblasts
The localization of resident Golgi proteins has been exam-
ined previously in COG1- and COG2-deficient CHO cells as
well as in COG3-depleted HeLa cells (Oka et al., 2004; Zolov
and Lupashin, 2005). In these studies, a subset of Golgi
proteins (termed GEARs) were identified whose intracellu-
lar distribution and stability was COG sensitive. These pro-
teins included the Golgi matrix components GM130 and
giantin; the Golgi SNAREs GS15, GS27, and GS28; and the
cis-Golgi glycoprotein GPP130. Because no gross alteration
in the localization of the cis/medial Golgi marker giantin
and the trans-Golgi marker GalT was observed in P1 fibro-
blasts, we examined the steady-state localization of the
COG-sensitive Golgi proteins by immunofluorescence mi-
croscopy in an effort to determine whether their localization
was affected. GM130 and GPP130 exhibited a typical Golgi
ribbon-like staining pattern in control cells and this distri-
bution was similar in patient fibroblasts (Figure 4). GS27 had
a diffuse Golgi staining pattern in both cell types, consistent
with both Golgi and ERGIC localization. Although GS15
exhibits a polarized Golgi localization in control cells, the
staining of this protein was substantially lower and more
dispersed in P1 cells. The abnormal localization of GS15 in
these cells was COG7-dependent because its distribution
and intensity in COG7-corrected P1 cells was comparable
with control cells (Figure 5A). The localization of GS28 in
COG7-deficient fibroblasts was also abnormal but to a lesser
extent compared with GS15.
The presence of clusters containing giantin and GalT
predominantly in P1 but not control fibroblasts after pro-
Figure 3. Recovery of Golgi localization of giantin is not sub-
stantially altered in COG-deficient patient fibroblasts after BFA
washout. (A) Control, patient, and COG7-corrected patient fibro-
blasts were treated with 0.25 g/ml BFA for 60 min followed by
washout of the drug as described in Materials and Methods. The
localization of giantin at various recovery times was followed by
immunofluorescence. The arrows indicate the stable, residual
Golgi-like staining of giantin after BFA treatment. Bar, 20 m (B)
Stained cells within a population (200 –300) were classified into
one of four typical staining patterns (1– 4r) reflecting the recovery
of Golgi localization. Pattern 1r, ER localization; pattern 2r, ER-
GIC localization; pattern 3r, Golgi mini-stacks; and pattern 4r,
Golgi ribbon. The average percentage of cells within these clas-
sifications in two independent experiments is shown. Errors rep-
resent SEs of the mean. a, cells with single, concentrated remnant-
like structures were counted as exhibiting full ER localization
(#1r; see Materials and Methods).
Table 1. Quantitation of clusters in control and P1 fibroblasts after
BFA treatment
Golgi protein
% of cells with
clusters
P1COG7CTRL P1
GM130 0 2  1 N.D.
Giantin 3  2 87  1 7  2
GPP130 0 46  4 3  1
GS27 0 0 N.D.
GS28 1  1 38  4 N.D.
GalT 0 30  7 0
Cells were treated with 0.25 g/ml BFA for 60 min, and cells with
single juxtanuclear clusters within populations of 200–300 were
quantitated. Values represent the average of two to three indepen-
dent experiments. Errors represent SDs. N.D., not determined.
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longed BFA treatment indicated that differences in the local-
ization of Golgi resident proteins may emerge at nonequi-
librium conditions. Therefore, the localization of the GEAR
proteins was examined after BFA treatment to determine
whether formation of these clusters was a general phenom-
enon. As shown in Figure 4, GPP130 redistributed com-
pletely to the ER in control fibroblasts after BFA treatment.
GS28 and GS15 exhibit a more granular ER-like staining
pattern in these cells upon BFA treatment. Although the
majority of these proteins also redistributed to the ER in P1
fibroblasts, clusters similar to that observed for giantin and
GalT were noted for GPP130 and GS28 after treatment with
BFA. Because of the weak staining of GS15 in untreated P1
fibroblasts, it is unclear whether these structures are present.
In contrast, GS27 and GM130 redistribute primarily to punc-
tate structures uniformly dispersed toward the cell periph-
ery in response to BFA treatment in both control and patient
fibroblasts. These punctate structures are characteristic of
protein accumulation in ER exit sites and have been previ-
ously observed for GM130 as well as other proteins such as
ERGIC-53 (Lippincott-Schwartz et al., 1990; Ward et al., 2001;
Puri and Linstedt, 2003). Importantly, no juxtanuclear, clus-
ter staining of GM130 and GS27 was detected in either
control or P1 fibroblasts. In addition, clusters were not
readily detected in BFA-treated COG7-corrected patient fi-
broblasts (Figure 5C), demonstrating the COG-dependent
nature of these structures. The percentage of cells that ex-
hibit clusters upon BFA treatment is summarized in Table 1.
Although the relative number of cells with these structures
varies between proteins, only those proteins that redistrib-
ute completely within the ER upon BFA treatment in control
cells (GalT, GPP130, giantin, and GS28) develop these
unique structures in P1 fibroblasts.
To determine whether differences in localization correlate
with decreases in steady-state levels, the relative amounts of
the various Golgi proteins was assessed by immunoblotting.
We found a striking reduction in GS15 in both P1 and P2
fibroblasts (Figure 6A). This decrease was COG7 dependent
because GS15 levels were normalized in COG7-corrected P1
fibroblasts (Figure 6B). Consistent with their normal staining
pattern, the levels of GS27 and COP were not substantially
reduced in P1 fibroblasts (Figure 6B). Treatment of P1 cells
with either the proteasome inhibitor MG132 or the lysoso-
mal protease inhibitors leupeptin and pepstatin A failed to
increase the levels of GS15 (Figure 6C). Although we found
decreased levels of multiple Golgi proteins, including GPP130,
giantin, GalT, and GS28 in some experiments, the reduction in
these proteins was highly variable, and, in some cases did not
seem to be dependent on COG7 because the levels were also
decreased in COG7-corrected P1 fibroblasts. Furthermore, little
or no decrease in the levels of these proteins was observed in
P2 fibroblasts (our unpublished data).
The Nature of the Unique Membrane Clusters in P1
Fibroblasts
Because of the singular juxtanuclear location of the clusters,
we investigated the possibility that the accumulation of
Figure 4. Immunofluorescence localization of Golgi
proteins in the presence and absence of BFA. Control
and patient fibroblasts were treated with or without
0.25 g/ml BFA for 60 min, and the localization of the
marker proteins was followed by immunofluorescence.
Arrows indicate the presence of remnant-like structures
for some proteins. Note that some Golgi proteins redis-
tribute to the ER while others (GM130 and GS27) redis-
tribute predominantly to ER exit sites. Bar, 20 m.
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giantin observed in BFA-treated P1 cells occurred at the
microtubule-organizing center (MTOC). The MTOC, which
can be specifically labeled by anti--tubulin, serves to orga-
nize pre-Golgi membranes after their exit from the ER (Oakley
and Akkari, 1999; Rios and Bornens, 2003). The -tubulin
staining in patient and control cells was not altered in the
presence or absence of BFA (Figure 7A). There is little or no
colocalization between -tubulin and giantin in untreated
control and P1 cells consistent with the distinct apposition of
the Golgi stack and the MTOC. On BFA treatment, giantin,
which redistributes exclusively to the ER in control cells,
fails to localize with -tubulin. In contrast, the giantin-pos-
itive clusters observed in P1 cells show strong colocalization
with -tubulin. These results indicate that the accumulation
of Golgi markers in clusters is coincident with the MTOC.
The clusters are sensitive to nocodazole treatment, provid-
ing further support for the presence of microtubules (Figure
7B). ERGIC-53 is largely excluded from these structures
upon BFA treatment, indicating that they are not ER export
sites (our unpublished data).
The Steady-State Localization of ERGIC-53 Is Altered in
P1 Fibroblasts
We next examined the localization of the cargo receptor
ERGIC-53, a protein that defines the ERGIC and actively
recycles between the ER and Golgi (Itin et al., 1995). If the
retrograde transport of ERGIC-53 was impaired in the
COG7-deficient fibroblasts, the steady-state pattern of this
protein might be altered. ERGIC-53 staining of control cells
revealed a pattern that has characteristics of both the Golgi
and the ER and is herein referred to as a classic ERGIC
pattern. In contrast, ERGIC-53 staining in many P1 fibro-
blasts more strongly resembled a Golgi-like ribbon structure
(abnormal ERGIC pattern). This abnormal ERGIC pattern
was seen in 50 7% of P1 cells versus only 5 2% of control
cells. The abnormal ERGIC pattern was COG-dependent
because ERGIC-53 localization in COG7-corrected cells was
indistinguishable from control cells (Figure 5B).
To determine whether the abnormal localization of ERGIC-
53 in P1 cells colocalizes with the Golgi, double immunoflu-
orescence studies with ERGIC-53 and giantin were per-
formed. There was no overlap between the two proteins in
control fibroblasts (Figure 8, second row). In contrast, there
was a high degree of colocalization in P1 cells. The majority
of ERGIC-53 clustered in regions surrounding giantin-posi-
tive Golgi membranes, indicating that the localization of the
protein was shifted to the cis-Golgi face. Prolonged exposure
of cells to lower temperature has been shown to result in an
accumulation of ERGIC-53 in the ERGIC compartment and a
shift of the compartment closer to the cis-Golgi membranes
(Klumperman et al., 1998). Because the intracellular distri-
bution of ERGIC-53 in P1 cells bears similarity to the effects
of lower temperature on ERGIC-53 localization, control and
P1 cells were cultured at 15°C for 3 h and ERGIC-53 local-
ization analyzed by immunofluorescence. As shown in Fig-
ure 8, the localization of ERGIC-53 in control cells kept at
15°C is consistent with an accumulation of ERGIC-53 in the
ERGIC compartment and a shift toward the cis-Golgi. In
contrast, ERGIC-53 staining in P1 fibroblasts was not detect-
ably altered at lower temperature, indicating that ERGIC-53
had already undergone a shift in its localization. The effects
of lower temperature are distinct from the action of BFA as
demonstrated in Figure 8. Therefore, proteins that actively
recycle between the Golgi and ER are altered by COG7
deficiency.
Figure 6. Steady-state level of GS15 is reduced in patient fibro-
blasts. Representative immunoblots are shown for the various pro-
teins. In all cases, 100 g of total protein was resolved on 15%
SDS-PAGE gels. (A) Western blot analysis of GS15 levels in control,
P1, and P2 fibroblasts. (B) Western blot analysis of control, P1, and
COG7-corrected P1 fibroblast lysates. GS15 levels are normalized in
COG7-corrected patient fibroblasts. (C) P1 cells were treated with
either 25 M MG132 for 10 h or 150 M leupeptin and 100 M
pepstatin A for 16 h before sample preparation. Note that neither
lysosomal or proteasomal inhibition restored GS15 levels.
Figure 5. Abnormal localization of ERGIC and Golgi proteins is
normalized in COG7-corrected patient fibroblasts. The localization
of GS15, ERGIC-53, and GPP130 were followed by immunofluores-
cence. Golgi localization of GS15 (A) and ERGIC localization of
ERGIC-53 (B) is restored in COG7-corrected P1 fibroblasts. (C) P1
and COG7-corrected P1 fibroblasts were treated with 0.25 g/ml
BFA for 60 min. Note the lack of BFA-induced clusters in the
COG7-corrected cells. Quantitation of the frequency of GPP130-
positive remnants observed in COG7-corrected cells is shown in
Table 1.
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DISCUSSION
These studies have uncovered a number of alterations in
Golgi protein localization, stability and trafficking in COG7-
deficient fibroblasts. One of the most striking findings in this
study was the delay in retrograde trafficking of giantin and
GalT upon treatment of the COG7-deficient fibroblasts
with BFA (Figure 1 and Supplemental Figure S1). Although
much attention has been focused on the role of the COG
complex in intra-Golgi and ER-to-Golgi transport, our re-
sults indicate that COG7 is also required for efficient Golgi-
to-ER retrograde transport. The block in mainly retrograde
(but not anterograde) transport between the ER and Golgi is
clearly evidenced by the redistribution of ERGIC-53 to the
cis-Golgi compartment in patient fibroblasts (Figure 8).
One can envision multiple mechanisms whereby Cog7p
deficiency results in a delayed response to BFA. It is known
that after treatment with BFA, the coat proteins COPI and
AP-1 are rapidly released from the Golgi membrane into the
cytosol, allowing tubules to form that subsequently fuse
with the ER (Lippincott-Schwartz et al., 1990; Lippincott-
Schwartz and Zaal, 2000; Altan-Bonnet et al., 2004). There-
fore, the slower tubule formation in BFA-treated patient
fibroblasts could potentially result from delayed COPI re-
lease. However, our finding that COP and the trans-Golgi
network adaptor protein AP-1 were released at the same rate
in control and patient cells (Figure 2) suggests an alternate
mechanism. Because BFA-induced tubulation has been
shown to occur along microtubules (Lippincott-Schwartz et
al., 1990; Sciaky et al., 1997; Duran et al., 2003), the COG
complex may facilitate Golgi-to-ER transport by tethering
retrograde-bound tubules to the cytoskeleton. If this is the
mechanism of action, it is notable that the COG complex
would be acting independently of COPI. Because recent
studies have shown that BFA-induced tubules fuse with the
Figure 7. Giantin colocalizes with the MTOC
marker -tubulin in BFA-treated P1 but not control
fibroblasts (A) Control and patient fibroblasts were
treated with or without 0.25 g/ml BFA for 60 min
and stained for either giantin or -tubulin. The
localization of these proteins was analyzed by con-
focal immunofluorescence. The asterisk denotes
the single, juxtanuclear staining of the MTOC. Bar,
20 m. (B) Cells were treated with 0.25 g/ml BFA
for 60 min followed by 30-min exposure to 10 M
nocodazole. Fixed cells were then stained for gian-
tin using a specific polyclonal antibody. Note the
sensitivity of the remnant-like structures to no-
codazole indicating the presence of microtubules.
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ER at ER exit sites, loss of Cog7p could result in failure of
tubules to fuse properly with the ER at these sites (Mardones
et al., 2006). Although COG may play a direct role in the
tethering and fusion of BFA-induced tubules, secondary loss
of other proteins may contribute to this effect. Finally, a
defect in ER-Golgi recycling, as evidenced by the abnormal
localization of multiple recycling proteins such as ERGIC-53,
may lead to changes in the lipid composition of the Golgi
that are unfavorable for tubule formation.
After prolonged BFA treatment of patient fibroblasts, sev-
eral of the Golgi proteins examined accumulated in nocoda-
zole-sensitive solitary clusters that colocalized with the
MTOC. These clusters have a different appearance from
the previously noted BFA-induced Golgi-like “remnants,”
which have a scattered, peripheral punctate distribution and
are now considered to represent ER exit sites (Miles et al.,
2001; Ward et al., 2001; Puri and Linstedt, 2003). The MTOC-
associated clusters were not detected in the COG7-deficient
fibroblasts in the absence of BFA treatment, so it is unclear
whether Golgi proteins accumulate at the MTOC at steady
state in the mutant cells or whether these structures are a
specific consequence of BFA-induced overloading of the ER
export system with Golgi proteins in cells impaired in ve-
sicular trafficking. Coincident with its role in positioning the
Golgi complex, the microtubule-organizing center serves to
organize pre-Golgi intermediates before their transport
along microtubules to the Golgi (Lippincott-Schwartz, 1998;
Rios and Bornens, 2003). Thus, the presence of Golgi pro-
teins at the MTOC under pressure of BFA may represent the
failure of pre-Golgi membranes to efficiently move away
from the centrosome in the absence of a functional COG
complex. This would be consistent with the known interac-
tion between COPI and the COG complex because the trans-
port of vesicles from the ERGIC to the Golgi has been shown
to involve COPI (Aridor et al., 1995; Scales et al., 1997;
Stephens et al., 2000). Indeed, the accumulation of ERGIC-53
in an atypical ERGIC compartment in patient fibroblasts at
steady state might also reflect a block in ERGIC-to-Golgi
transport.
The striking loss of GS15 in patient fibroblasts and the
dependence of this reduction on COG complex subunits are
consistent with recent observations in COG-deficient CHO
cells (Oka et al., 2004). In this study by Krieger and col-
leagues, a reduction in the level of additional Golgi proteins
(termed GEARs) was noted. Although decreases in some
GEAR proteins such as GS28 and GPP130 were observed in
P1 fibroblasts, this reduction was highly variable and was
not seen in P2 fibroblasts. The observation by Lupashin and
coworkers that GS15 is mislocalized in CCD vesicles upon
depletion of COG3 in HeLa cells reinforces the hypothesis
that loss of COG results in mislocalization of Golgi proteins
and their eventual degradation (Zolov and Lupashin, 2005).
Because this degradation might occur via either ER-associ-
ated proteasomal or lysosomal pathways, we sought to de-
termine the degradative pathway responsible for the GS15
reduction. Surprisingly, inhibition of the proteasome or ly-
sosomal proteases failed to restore GS15 in patient fibro-
blasts. The mechanism underlying the depletion of GS15 in
patient fibroblasts is still unclear.
Although the alterations in protein trafficking between the
ER and Golgi may be a direct consequence of impaired COG
complex integrity, these abnormalities could also be due to
the secondary loss of recycling factors (i.e., SNAREs) re-
quired for this transport. In support of this notion, small
interfering RNA (siRNA)-mediated knockdown of COG3
(Zolov and Lupashin, 2005) or GS15 (Xu et al., 2002) in HeLa
cells produced a similar phenotype, namely, the redistribu-
tion of multiple Golgi markers, including GalT, to dis-
persed, punctate vesicular structures. Because CDG-IIe fi-
broblasts are deficient in several COG subunits as well as
GS15, it is surprising that more prominent differences in
Golgi protein localization were not observed. Because
siRNA knockdown experiments result in acute posttran-
scriptional depletion of the target protein, the lack of Golgi
protein redistribution in the patient fibroblasts may reflect
compensation for the genetic deficiency of COG7 (i.e., up-
regulation or down-regulation of other trafficking proteins).
Because the COG subunits 1–4 (comprising lobe A) are
present at normal steady-state levels and localized to the
Golgi in COG7-deficient fibroblasts (Wu et al., 2004, Oka et
al., 2005), it is also possible that these subunits may form a
partially functional COG subcomplex.
We previously demonstrated decreased sialylation of N-
and O-linked oligosaccharides, reduced activity of multiple
glycosyltransferases and nucleotide-sugar transporters and
abnormal trafficking of a GFP-sialyltransferase chimera in
COG7-deficient fibroblasts. Here, the observation that GalT
exhibits altered trafficking in patient fibroblasts provides
additional support for the hypothesis that altered recycling
of glycosylation enzymes between the ER and Golgi may
lead to altered localization, activity, or both. The lack of any
Figure 8. ERGIC-53 localization is altered in COG7-deficient fibro-
blasts. Control and patient fibroblasts were either treated with 1
g/ml BFA for 30 min. or incubated at 15°C for 3 h as indicated. The
localization of ERGIC-53 (first, third, and fourth rows) was followed
by immunofluorescence. Arrows indicate representative cells with
abnormal concentration of ERGIC-53 in structures resembling the
cis-Golgi. For the colocalization studies (second row), giantin is
stained in red and ERGIC-53 in green. Bar, 20 m.
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detectable defects in galactosylation in COG7-deficient fi-
broblasts despite the modest reduction in steady-state levels
of GalT is not surprising because fibroblasts from a GalT-
deficient CDG-IId patient, exhibited only minor changes in
galactosylation of N-linked oligosaccharides despite a 95%
reduction in enzyme activity (Hansske et al., 2002). The COG
complex has been proposed to facilitate COPI-dependent
intra-Golgi retrieval of resident proteins and enzymes
(Suvorova et al., 2002; Ungar et al., 2002; Zolov and Lupashin,
2005). Therefore, it is possible that mislocalization of such
enzymes to post-Golgi compartments such as endosomes or
lysosomes may contribute to decreased activity or stability
as has been recently shown in COG-deficient yeast cells
(Bruinsma et al., 2004). Because efficient glycosylation re-
quires the transport of nucleotide-sugars into the Golgi lu-
men via nucleotide-sugar transporters in addition to the
action of glycosyltransferases, the mislocalization and/or
degradation of the nucleotide-sugar transporters may be
sufficient to disrupt glycosylation reactions in the absence of
substantial effects on glycosyltransferase stability. A more
precise determination of the mechanisms responsible for the
observed glycosylation defects in P1 fibroblasts (i.e., de-
creased sialylation) will require the generation of appropri-
ate antisera.
These results have several implications regarding the
pathological consequences of COG deficiency. The multiple
developmental abnormalities seen in the CDG-IIe patients
stress the vital role of the COG complex in human develop-
ment. Because efficient glycosylation is required for the
proper development and function of many systems, altered
modification of oligosaccharides due to decreased activity of
glycosylation enzymes may account for many of the clinical
features noted in these patients. In addition to the impact of
abnormal glycosylation, loss of proper protein recycling in
COG-deficient cells could have other relevant outcomes.
Golgi disassembly and reassembly are necessary steps dur-
ing mitosis (Misteli, 1996). The inability to efficiently trans-
port proteins or link vesicles to the cytoskeleton upon Golgi
reassembly in COG-deficient cells may result in defective
growth of rapidly dividing cells or impaired ability to mi-
grate, especially in light of the high demand for this process
during development. The impact of COG deficiency on sper-
matogenesis, a sensitized developmental system involving
cytokinesis and the assembly on specialized Golgi architec-
ture, has been previously observed in the COG5-deficient
Drosophila mutant four-way stop (fws) (Farkas et al., 2003).
Finally, the abnormal localization of ERGIC-53 could impact
the levels of several blood coagulation proteins in the CDG-
IIe patients. Because ERGIC-53 has been shown to be neces-
sary for the sorting and transport of Factor V and Factor VIII,
its inability to recycle efficiently between the ER and cis-
Golgi may lead to a failure in the proper sorting and export
of these coagulation factors (Nichols et al., 1998).
Many patients with the diagnosis of CDG have unknown
defects, and it is likely that a subset of them will have
abnormalities in components of their protein trafficking ma-
chinery. Determination of the molecular defect via analysis
of patient fibroblasts is often confounded by the lack of
observable phenotypes (i.e., changes in glycan structure).
Although COG7-deficient patient fibroblasts exhibit only
subtle changes in their glycosylation profile, clear differences
can be observed in their response to BFA. Thus, our results
show the value of nonequilibrium conditions (i.e., BFA treat-
ment) to bring out defects that may not be evident under
steady-state conditions. We suggest that this simple proce-
dure become a routine component of the analysis of fibro-
blasts from these patients.
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